Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids

被引:278
作者
Reddy, ST
Wadleigh, DJ
Grijalva, V
Ng, C
Hama, S
Gangopadhyay, A
Shih, DM
Lusis, AJ
Navab, M
Fogelman, AM
机构
[1] Univ Calif Los Angeles, Dept Med, Div Cardiol, Atherosclerosis Res Unit, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA
[4] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
关键词
paraoxonase; MM-LDL; PON3; atherosclerosis; oxidized lipids;
D O I
10.1161/01.ATV.21.4.542
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Paraoxonase-1 (PON1) is a secreted protein associated primarily with high density lipoprotein (HDL) and participates in the prevention of low density lipoprotein (LDL) oxidation. Two other paraoxonase (PON) family members, namely, PON2 and PON3, have been identified. In this study, we report the cloning and characterization of the human PON3 gene from HepG2 cells. Tissue Northern analysis identifies an approximate to1.3-kb transcript for PON3 primarily in the liver. PON3-specific peptide antibodies detect an approximate to 40-kDa protein associated with HDL and absent from LDL. Pretreatment of cultured human aortic endothelial cells with supernatants from HeLa Tet On cell lines overexpressing PON3 prevents the formation of mildly oxidized LDL and inactivates preformed mildly oxidized LDL. In contrast to PON1, PON3 is not active against the synthetic substrates paraoxon and phenylacetate. Furthermore, PON3 expression is not regulated in HepG2 cells by oxidized phospholipids and is not regulated in the livers of mice fed a high-fat atherogenic diet.
引用
收藏
页码:542 / 547
页数:6
相关论文
共 31 条
  • [1] A SPECTROPHOTOMETRIC MICROTITER-BASED ASSAY FOR THE DETECTION OF HYDROPEROXY DERIVATIVES OF LINOLEIC-ACID
    AUERBACH, BJ
    KIELY, JS
    CORNICELLI, JA
    [J]. ANALYTICAL BIOCHEMISTRY, 1992, 201 (02) : 375 - 380
  • [2] Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities - Selective action of human paraoxonase allozymes Q and R
    Aviram, M
    Billecke, S
    Sorenson, R
    Bisgaier, C
    Newton, R
    Rosenblat, M
    Erogul, J
    Hsu, C
    Dunlop, C
    La Du, B
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (10) : 1617 - 1624
  • [3] Overexpression of apolipoprotein all in transgenic mice converts high density lipoproteins to proinflammatory particles
    Castellani, LW
    Navab, M
    VanLenten, BJ
    Hedrick, CC
    Hama, SY
    Goto, AM
    Fogelman, AM
    Lusis, AJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (02) : 464 - 474
  • [4] Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation
    Draganov, DI
    Stetson, PL
    Watson, CE
    Billecke, SS
    La Du, BN
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (43) : 33435 - 33442
  • [5] Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response
    Feingold, KR
    Memon, RA
    Moser, AH
    Grunfeld, C
    [J]. ATHEROSCLEROSIS, 1998, 139 (02) : 307 - 315
  • [6] FOGELMAN AM, 1988, J LIPID RES, V29, P1243
  • [7] DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM
    HAVEL, RJ
    EDER, HA
    BRAGDON, JH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1955, 34 (09) : 1345 - 1353
  • [8] Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus
    Hegele, RA
    Connelly, PW
    Scherer, SW
    Hanley, AJG
    Harris, SB
    Tsui, LC
    Zinman, B
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (10) : 3373 - 3377
  • [9] Hegele RA, 1998, CLIN GENET, V54, P394
  • [10] Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases
    Imai, Y
    Morita, H
    Kurihara, H
    Sugiyama, T
    Kato, N
    Ebihara, A
    Hamada, C
    Kurihara, Y
    Shindo, T
    Oh-hashi, Y
    Yazaki, Y
    [J]. ATHEROSCLEROSIS, 2000, 149 (02) : 435 - 442